Related Experiment Video
Updated: Apr 26, 2026
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis
Yoshihide Asano1, Hironobu Ihn, Masatoshi Jinnin
1Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Abstract:
Matrix metalloproteinase-13 (MMP-13), a member of the collagenase family, has been implicated in the pathogenesis of connective tissue diseases characterized by extracellular matrix remodeling. Since serum MMP-13 levels reflect disease severity of systemic sclerosis and localized scleroderma, we evaluated the clinical significance of serum MMP-13 levels in eosinophilic fasciitis (EF). All the EF patients had serum MMP-13 levels lower than the mean - 2SD of healthy controls. Serum MMP-13 levels were also significantly decreased in EF patients compared with diffuse cutaneous systemic sclerosis, limited cutaneous systemic sclerosis, and generalized morphea patients. Although serum MMP-13 levels did not reflect any clinical and serological features of EF, these results indicate that MMP-13 may be involved in the development of this disease.
Insights
Serum levels of matrix metalloproteinase-13 (MMP-13) were significantly lower in patients with eosinophilic fasciitis (EF) compared to healthy individuals. This suggests MMP-13 may play a role in EF pathogenesis.
Area of Science:
- Biochemistry
- Immunology
- Rheumatology
Background:
- Matrix metalloproteinase-13 (MMP-13), a collagenase, is involved in extracellular matrix remodeling in connective tissue diseases.
- Elevated serum MMP-13 levels correlate with disease severity in systemic sclerosis and localized scleroderma.
Purpose of the Study:
- To investigate the clinical significance of serum MMP-13 levels in eosinophilic fasciitis (EF).
- To determine if MMP-13 levels reflect disease severity or clinical features in EF.
Main Methods:
- Serum MMP-13 levels were measured in patients with EF.
- MMP-13 levels in EF patients were compared to healthy controls and patients with other sclerosing disorders (systemic sclerosis, generalized morphea).
Main Results:
- All EF patients exhibited serum MMP-13 levels below the mean - 2SD of healthy controls.
- Serum MMP-13 levels were significantly decreased in EF patients compared to diffuse cutaneous systemic sclerosis, limited cutaneous systemic sclerosis, and generalized morphea patients.
- Serum MMP-13 levels did not correlate with any clinical or serological features of EF.
Conclusions:
- Serum MMP-13 levels are significantly reduced in eosinophilic fasciitis.
- MMP-13 may be implicated in the pathogenesis of eosinophilic fasciitis, despite decreased serum levels.
